OPL 13.3% 2.6¢ opyl limited

Opyl matters, page-7

  1. 1,173 Posts.
    lightbulb Created with Sketch. 588
    Opyl is claiming credit for predicting a positive interim outcome of the $DXB/Dimerix ACTION3 Phase 3 trial of DMX-200 in FSGS Kidney Disease.

    Bernice Averion, Medtech Marketing Marketing Manager of OPL's TrialKey business:

    "...Opyl foresaw this success, predicting a high probability of 74.51% even before the official results were revealed.

    "As a result, DXB's share price has experienced a notable surge, underlining the potential benefits of predictive tools like TrialKey for investors.

    "Imagine having the foresight to spot viable investments before the market catches on!"
 
watchlist Created with Sketch. Add OPL (ASX) to my watchlist
(20min delay)
Last
2.6¢
Change
-0.004(13.3%)
Mkt cap ! $4.439M
Open High Low Value Volume
2.9¢ 2.9¢ 2.6¢ $5.694K 212.4K

Buyers (Bids)

No. Vol. Price($)
1 300000 2.5¢
 

Sellers (Offers)

Price($) Vol. No.
2.6¢ 1611 1
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
2.6¢
  Change
-0.004 ( 13.3 %)
Open High Low Volume
2.7¢ 2.7¢ 2.6¢ 158016
Last updated 15.44pm 14/06/2024 ?
OPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.